Market Closed -
Other stock markets
|
Pre-market 05:52:58 pm | |||
307.4 USD | +0.05% | 309.4 | +0.64% |
05/06 | Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints | MT |
05/06 | Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.72% | 165B | |
+42.69% | 749B | |
+38.82% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+11.22% | 216B | |
-2.66% | 214B | |
+2.64% | 167B | |
+0.36% | 123B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : to Acquire Five Prime Therapeutics for $1.9 Billion